Back to the overview page

Ivan (I) Bank MD PhD

Clinical Transfusion Research


Research interests
  • Hematopoietic stem cell mobilization
  • Donation procedure
  • Thrombosis
  • Hemostasis
  • Hemolytic anemia
2011-presentSpecialization Transfusion Medicine, Sanquin Research; Researcher Jon J van Rood Center for Clinical Transfusion Research, Leiden
2011-presentDept of Internal Medicine, Hospital Lange Land, Zoetermeer
2011-presentAssistant professor, Faculty of Medicine, Leiden University Medical Centre, Leiden
2010-2011Europdonor Foundation, Leiden
2009Internist-hematologist, Leiden University Medical Centre, Leiden
2003PhD, Dept of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam
1999Medical doctor, University of Amsterdam, Amsterdam
Sanquin publications
Other publications

Bank I, Jansen C, Postma B, Geelhoed-Duijvestijn PHLM, Meijssen MAC. Case report of an unexpected combination of tropical microorganisms causing severe illness. Infect Dis Clin Pract 2009; 17:52-4.

Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamulyák K, Prins MH, Büller HR, van der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-22.

Bank I, Busari JO. Crohn’s disease, autoimmune thyroiditis and beta-thalassemia trait in an adolescent: an unusual combination of diseases. Eur J Paediatrics 2008; 167:1343-6.

Bank I, Eikenboom HC. Een praktische benadering van de patiënt met bloedingsneiging. Ned Tijdschr Hematol 2008; 5:314-20.

Bank I, Veldkamp RF. Behandeling recidief longembolie gedurende gebruik van acenocoumarol. Longartsen Vademecum 2007; 10:1-5.

Lijfering W, Coppens M, van de Poel MHW, Middeldorp S, Hamulyák K, Bank I, Veeger NJGM, Prins MH, Büller HR, van der Meer J. The risk of venous and arterial thrombosis in hyperhomocysteinemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98:457-63.

Bank I, van de Poel MHWCoppens M., Hamulyák K, Prins MH, van der Meer J, Veeger NJGM, Büller HR, Middeldorp S. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c: a prospective family cohort study. Thromb Haemost 2007; 98:1040-4.

Bank I. Current treatment of pulmonary embolism. Medicinski Glasnik 2007; 22:19-24.

Coppens M, van de Poel MH, Bank I, Hamulyák K, van der Meer J, Veeger NJ, Prins MH, Büller HR, Middeldorp S. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108:2604-7.

Bank I, Libourel EJ, Middeldorp S, Hamulyák K, van Pampus ECM, Koopman MMW, Prins MH, van der Meer J, Büller HR. Elevated levels of FVIII:c within families are associated with increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3:79-84.

Libourel EJ, Bank I, Veeger NJ, Hamulyák K, Middeldorp S, Büller HR, van der Meer J. Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a restrospective study. Blood Coagul Fibrinolysis 2005; 16:135-40.

Bank I, Scavenius MPRB, Büller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thrombosis Research 2004;113:7-12.

Bank I, Tick LW, Hutten BA, Kramer MH, Middeldorp S, Büller HR. Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis. Pathophysiol Haemost Thromb 2004; 33:192-6.

Bank I, Libourel EJ, Middeldorp S, van Pampus ECM, Koopman MMW, Hamulyák K, Prins MH, van der Meer J, Büller HR. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 164:1932-7.

Locadia M., Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen C, Middeldorp S, Bank I, van der Meer J, Hamulyák K, Prins MH. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost 2004; 92:1336-41.

Middeldorp S, van de Poel M, Bank I, Hamulyák K, Libourel EJ, Koopman MMW, Prins MH, van der Meer J, Büller HR. Unselected women with elevated levels of factor VIII:c or homocysteine are not at increased risk for obstetric complications. Thromb Haemost 2004; 92:787-90.

Bank I, Libourel EJ, Middeldorp S, van der Meer J, Büller HR. High rate of skin complications due to low-molecular weight heparins in pregnant women. Journal of Thrombosis and Haemostasis 2003;1:568-70.

Bank I. Een patiënt met ‘milde’ hemofilie. Tandarts Praktijk 2003; 24:26-8.

Bank I, Mac Gillavry MR, Brandjes DPM, Büller HR. Does the location of deep venous thrombosis of the leg determine the risk of the post-thrombotic syndrome? Journal of Thrombosis and Haemostasis 2003;1:2058-9.

Bank I, Middeldorp S, Prins MH. Oral contraceptives and cardiovascular disease. In: Brenner B, Mander VJ, Conard J, eds. Womens’ Issues in Thrombosis and Haemostasis. 1st ed. London: Martin Dunitz Publishers, 2002, chapter 8, p. 121-33.

Libourel EJ, Bank I, Middeldorp S, Büller HR,van der Meer J. Cosegregation of thrombophilic disorders in factor V Leiden carriers: the contribution of FVIII:c, factor XI, TAFI and lipoprotein (a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87:1068-73.

Bank I, Middeldorp S, Büller HR. Hereditary and acquired thrombophilia. Semin Respir Crit Care Med. 2000; 21:483-91.

Bank I, Koopman MMW. De thuisbehandeling van diepe veneuze trombose: minder belastend voor de patiënt. Pharmaceutisch Weekblad 2000; 135: 981-5.

Last edited on: 25 April 2013
Back to the overview page